Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease
about
Iron and neurodegeneration: from cellular homeostasis to diseaseTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesA novel profluorescent probe for detecting oxidative stress induced by metal and H(2)O(2) in living cells.Advances in iron chelation: an update.Iron and mechanisms of neurotoxicityEryptosis as a marker of Parkinson's diseaseNeuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson's disease.Iron-binding and anti-Fenton properties of baicalein and baicalin.A novel H2O2-triggered anti-Fenton fluorescent pro-chelator excitable with visible light.Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunitiesNew Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases.Iron chelation and neuroprotection in neurodegenerative diseases.Brain iron accumulation in aging and neurodegenerative disorders.A glutathione derivative with chelating and in vitro neuroprotective activities: synthesis, physicochemical properties, and biological evaluation.Iron status and lipopolysaccharide regulate Ndfip1 by activation of nuclear factor-kappa B.Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation.Brain iron MRI: a biomarker for amyotrophic lateral sclerosis.Zinc-binding sites on selected flavonoids.In vivo iron quantification in collagenase-induced microbleeds in rat brain.Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.
P2860
Q21296730-ECD94B72-1C1B-42BD-A461-545368D30C69Q24289511-1BE99CF9-7A8D-4EDA-B980-DF1C3C337237Q34008089-84D93911-FB79-440C-9349-4F8CD76736CAQ34174307-C2E2C99E-198A-44BD-85F7-7FAFFEFEE748Q34460764-7EFF398B-20EC-46EB-9D49-FB447D9B0D52Q34585744-46D33227-2DF3-41C5-B66B-BEB143FBA436Q34733383-A1DDAE15-C9A5-4E99-B2AA-31A7BD59B0B4Q37137612-F4CD857D-5E94-41B2-90FF-D97C90D77CB7Q37240997-760DB9E5-FA83-46E2-956A-E145C3E2DAF9Q37605018-DD067825-8958-44B0-B7EE-F25156570EBBQ37703489-DB79F45D-79A9-4AED-9F8B-A4125698C7E3Q37821331-6D3BA6A7-DFC8-4D44-B478-E1D3DE8B1976Q38067144-ED1784A0-3DFA-4B46-828C-80ACA71F2620Q39084271-94E3BF20-95E5-4551-98AD-04DD30C1A6BBQ39094494-5537D9E1-E051-4D73-B90C-FD432B731723Q41515458-AEEBB973-DCEA-40AF-8BEB-1EA2D92454D4Q45404273-6C7F4285-6355-4BCC-BF95-73E7941F627CQ46852173-15DBCDEA-FF66-4993-B0D2-B5A9ADEB2198Q46880021-FA9171DC-7C6F-402C-A9C4-FA1E77C8AC97Q52679530-F36FCC26-D546-4E50-ACB6-2780871496BB
P2860
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease
@en
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease.
@nl
type
label
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease
@en
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease.
@nl
prefLabel
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease
@en
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease.
@nl
P2093
P2860
P1476
Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease
@en
P2093
Carlos A Perez
Maolin Guo
P2860
P304
P356
10.2174/157340708786305952
P577
2008-10-01T00:00:00Z